Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 320 (planned)
- Started
- Nov 23, 2026
- Main results expected
- Mar 10, 2031
- Fully finished
- Mar 10, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of dose-limiting toxicities (DLTs)
Measured over: Up to 21 days
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Measured over: Up to approximately 5 years
Occurrence of Serious Adverse Events (SAEs)
Measured over: Up to approximately 5 years
Occurrence of adverse event of special interests (AESIs)
Measured over: Up to approximately 5 years
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Measured over: Up to approximately 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07863024 · record last updated 2026-10-07 · checked 2026-11-09 15:47 UTC